Effectiveness of venous thromboembolism prophylaxis in patients with liver disease

Table 5 Multivariable analysis of risk factors for in-hospital mortality in patients with hepatic cirrhosis

	OR	95%CI
Prophylaxis group	1.03	0.73-1.43
Baseline albumin (g/dL)	0.68	0.52-0.88
Baseline hemoglobin (g/dL)	1.00	0.92-1.08
Male sex	1.00	0.71-1.42
Occurrence of primary endpoint	2.30	1.44-3.68
MELD < 10	0.05	0.02-0.14
MELD 10-19	0.09	0.04-0.21
MELD 20-29	0.31	0.13-0.70
MELD 30-39	0.93	0.39-2.20
All MELD categories compared to MELD score > 40

MELD: Model for end-stage liver disease.